CL2012003012A1 - Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. - Google Patents

Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.

Info

Publication number: CL2012003012A1
Authority: CL; Chile
Prior art keywords: salt; hydromorphone; naloxone; extended; preparation
Prior art date: 2010-05-10

Application number

CL2012003012A

Other languages

English (en)

Inventor

Helen Kathleen Danagher

Hassan Mohammad

Malcolm Walden

Geoffrey Gerard Hayes

Jonathon Oliver Whitehouse

Thinnayam Naganathan Krishnamurthy

Rincon Ricardo Alberto Vargas

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-10

Filing date

2012-10-26

Publication date

2014-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-10-26 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2014-02-21 Publication of CL2012003012A1 publication Critical patent/CL2012003012A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CL2012003012A 2010-05-10 2012-10-26 Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. CL2012003012A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10162428		2010-05-10

Publications (1)

Publication Number	Publication Date
CL2012003012A1 true CL2012003012A1 (es)	2014-02-21

Family

ID=42983574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003012A CL2012003012A1 (es)	2010-05-10	2012-10-26	Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.

Country Status (36)

Country	Link
US (1)	US9700508B2 (es)
EP (1)	EP2568967B2 (es)
JP (1)	JP5671609B2 (es)
KR (2)	KR20130030260A (es)
CN (2)	CN105832687A (es)
AP (1)	AP3441A (es)
AR (1)	AR083150A1 (es)
AU (1)	AU2011252039B2 (es)
BR (1)	BR112012028773A2 (es)
CA (1)	CA2739751C (es)
CH (1)	CH705273B1 (es)
CL (1)	CL2012003012A1 (es)
CO (1)	CO6640216A2 (es)
CR (1)	CR20120549A (es)
DE (1)	DE112011101605T5 (es)
DK (1)	DK178741B1 (es)
EA (1)	EA201291211A1 (es)
EC (1)	ECSP12012236A (es)
ES (1)	ES2408343B2 (es)
GB (1)	GB2492037A (es)
GT (1)	GT201200304A (es)
IL (1)	IL222772B (es)
MX (1)	MX347105B (es)
MY (1)	MY157673A (es)
NI (1)	NI201200157A (es)
NO (1)	NO20121414A1 (es)
NZ (2)	NZ603497A (es)
PE (1)	PE20130657A1 (es)
PH (1)	PH12012502011A1 (es)
SE (1)	SE1251371A1 (es)
SG (1)	SG184523A1 (es)
TN (1)	TN2012000488A1 (es)
TW (2)	TWI590835B (es)
UA (1)	UA106278C2 (es)
WO (1)	WO2011141488A2 (es)
ZA (1)	ZA201207603B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX347105B (es)	2010-05-10	2017-04-12	Euro Celtique Sa	Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
JP5840201B2 (ja)	2010-05-10	2016-01-06	ユーロ−セルティークエス．エイ．	活性剤を負荷した顆粒と追加の活性剤の組合せ
MX340188B (es)	2010-05-10	2016-06-30	Euro-Celtique S A *	Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
JP6129184B2 (ja) *	2012-09-03	2017-05-17	第一三共株式会社	ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
CA2881144A1 (en) *	2012-11-09	2014-05-09	Purdue Pharma	Pharmaceutical compositions comprising hydromorphone and naloxone
US9517208B2 (en) *	2013-03-15	2016-12-13	Purdue Pharma L.P.	Abuse-deterrent dosage forms
GB201313915D0 (en) *	2013-08-02	2013-09-18	Johnson Matthey Plc	Process
NZ719087A (en) *	2013-11-13	2017-12-22	Euro Celtique Sa	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) *	2014-03-28	2019-03-12	Purdue Pharma	Reducing drug liking in a subject
CN107205943A (zh) *	2014-12-08	2017-09-26	德威洛克制药有限公司	纳洛酮单剂和多层片剂
EP4103181A4 (en)	2020-02-14	2024-03-06	Teikoku Pharma USA, Inc.	TOPICAL NALOXONE COMPOSITION AND METHOD OF USE THEREOF

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE49324B1 (en)	1979-12-19	1985-09-18	Euro Celtique Sa	Controlled release compositions
US4457933A (en)	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
HU190619B (en)	1983-11-11	1986-09-29	Bezzegh,Denes,Hu	Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (de)	1984-06-13	1991-01-23	Röhm Gmbh	Verfahren zum Überziehen von Arzneiformen
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
GB8626098D0 (en)	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
EP0352361A1 (en)	1988-07-29	1990-01-31	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
FR2653337B1 (fr)	1989-10-23	1992-02-07	Dow Corning Sa	Element a liberation prolongee et procede pour le fabriquer.
US5662933A (en)	1993-09-09	1997-09-02	Edward Mendell Co., Inc.	Controlled release formulation (albuterol)
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
DE4443105C2 (de)	1994-12-03	1997-03-13	Hoechst Ag	Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en)	1996-09-20	2002-12-03	Ethypharm, Inc.	Effervescent granules and methods for their preparation
DE19651551C2 (de) *	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
CA2270975C (en)	1997-07-02	2003-04-01	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
KR100417489B1 (ko)	1997-12-22	2004-02-05	유로-셀티크 소시에떼 아노뉨	오피오이드 효능제／길항제 혼합물
ECSP003314A (es)	2000-01-11	2000-03-22		Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6716449B2 (en)	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
PT2092936E (pt) *	2000-02-08	2013-06-20	Euro Celtique Sa	Formulações orais de agonistas de opióides resistentes a adulteração
US20040115133A1 (en)	2000-05-10	2004-06-17	Wermeling Daniel P.	Intranasal opioid compositions
GB0102342D0 (en)	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
DE60238756D1 (de)	2001-05-11	2011-02-10	Endo Pharmaceuticals Inc	Opioid enthaltende arzneiform gegen missbrauch
CA2446738C (en) *	2001-05-11	2012-05-29	Endo Pharmaceuticals, Inc.	Abuse-resistant opioid dosage form
WO2002100382A2 (en)	2001-06-08	2002-12-19	Endo Pharmaceuticals, Inc.	Controlled release dosage forms using acrylic polymer, and process for making the same
US7332182B2 (en) *	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
IS7142A (is) *	2001-08-06	2004-02-05	Euroceltique S.A.	Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
DE20220910U1 (de)	2001-08-06	2004-08-05	Euro-Celtique S.A.	Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
HUP0401600A3 (en)	2001-08-23	2008-05-28	Organon Nv	Process for the preparation of 14-hydroxymorphine derivatives
DE10146275A1 (de)	2001-09-18	2003-04-24	Gruenenthal Gmbh	Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
DE10215131A1 (de) *	2002-04-05	2003-10-16	Euro Celtique Sa	Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
DE20308436U1 (de)	2002-04-05	2003-09-18	Euroceltique S.A., Luxemburg/Luxembourg	Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
EP1521571A1 (en)	2002-07-04	2005-04-13	Janssen Pharmaceutica N.V.	Solid dispersion comprising two different polymer matrixes
WO2004091622A1 (en)	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP1615646B2 (en)	2003-04-08	2022-07-27	Progenics Pharmaceuticals, Inc.	Pharmaceutical formulations containing methylnaltrexone
US20040259899A1 (en)	2003-04-08	2004-12-23	Sanghvi Suketu P.	Combination therapy for constipation
TWI350186B (en)	2003-04-30	2011-10-11	Purdue Pharma Lp	Tamper resistant transdermal dosage form
US9114199B2 (en)	2003-07-31	2015-08-25	Boston Scientific Scimed, Inc.	Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050079221A1 (en)	2003-10-10	2005-04-14	Groenewoud Pieter Jurjen	Ibuprofen narcotic composition and method for making same
US20050232987A1 (en)	2004-03-12	2005-10-20	Viswanathan Srinivasan	Dosage form containing a morphine derivative and another drug
US20050165038A1 (en)	2004-01-22	2005-07-28	Maxwell Gordon	Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP2194059A3 (en)	2004-02-06	2010-09-22	Euro-Celtique S.A.	Methods for making 3-O-protected morphinones and 3-O-protected morphinone dienol carboxylates
TWI350762B (en)	2004-02-12	2011-10-21	Euro Celtique Sa	Particulates
US9016221B2 (en)	2004-02-17	2015-04-28	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
TWI365880B (en)	2004-03-30	2012-06-11	Euro Celtique Sa	Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US7700626B2 (en)	2004-06-04	2010-04-20	Adolor Corporation	Compositions containing opioid antagonists
EP1604667A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en)	2004-08-31	2009-12-23	Euro Celtique Sa	Multiparticulates
US20060088594A1 (en)	2004-10-08	2006-04-27	Pilgaonkar Pratibha S	Highly compressible controlled delivery compositions of metformin
GB0423103D0 (en)	2004-10-19	2004-11-17	Boots Healthcare Int Ltd	Therapeutic agents
US20060205753A1 (en)	2005-01-20	2006-09-14	Israel Robert J	Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US20070259045A1 (en) *	2005-01-28	2007-11-08	Euro-Celtique S.A.	Alcohol Resistant Dosage Forms
EP1695700A1 (en) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
NL1028460C2 (nl) *	2005-03-04	2006-09-06	Sara Lee De Nv	Inrichting voor het bereiden en afgeven van al dan niet althans gedeeltelijk opgeschuimde dranken.
JP4741865B2 (ja)	2005-03-24	2011-08-10	共和薬品工業株式会社	ペルゴリド錠剤の製造方法
US20070026025A1 (en)	2005-04-12	2007-02-01	Aquegel Cosmetics, Llc	Topical ointment and method for making and using same
TWI366460B (en)	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007013047A2 (en)	2005-07-29	2007-02-01	Ranbaxy Laboratories Limited	Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en)	2005-08-04	2007-03-01	Yingxu Peng	Free flowing granules containing carbomer
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PT1962808E (pt)	2005-12-14	2010-10-29	Hoffmann La Roche	Formulação de precursor de fármaco para o hcv
US20070141147A1 (en)	2005-12-21	2007-06-21	Auriga Laboratories, Inc.	Sequential release pharmaceutical formulations
EP1813276A1 (en)	2006-01-27	2007-08-01	Euro-Celtique S.A.	Tamper resistant dosage forms
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de)	2006-10-26	2008-04-30	Evonik Röhm Gmbh	Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en)	2007-03-24	2011-08-17	Reckitt Benckiser Healthcare	A tablet having improved stability with at least two actives
HRP20140596T1 (hr)	2008-09-16	2014-08-01	Imuneks Farma Ilaç Sanayi Ve Ticaret A.S.	Uporaba opioidnih antagonista za pripravu lijeka za lijeäśenje degenerativnih bolesti mrežnice
ES2586439T3 (es)	2008-09-18	2016-10-14	Purdue Pharma Lp	Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
MX2011003047A (es)	2008-09-24	2011-04-14	Evonik Roehm Gmbh	Composicion farmaceutica de opioide de liberacion controlada ph dependiente con resistencia contra la influencia de etanol.
MX2011003050A (es)	2008-09-24	2011-04-11	Evonik Roehm Gmbh	Composicion farmaceutica de liberacion controlada ph dependiente para no opioides con resistencia contra la influencia de etanol.
DK2352494T3 (da)	2008-10-30	2019-10-28	Gruenenthal Gmbh	Nye og potente tapentadoldoseringsformer
US20100143486A1 (en)	2008-12-10	2010-06-10	Nipun Davar	Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
AU2009332963B2 (en)	2008-12-31	2015-02-05	Upsher-Smith Laboratories, Llc	Opioid-containing oral pharmaceutical compositions and methods
KR20110104097A (ko)	2009-01-09	2011-09-21	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	불소 함유 화합물 및 이의 사용방법
WO2010085641A1 (en)	2009-01-22	2010-07-29	Noramco, Inc.	Process for preparing particles of opioids and compositions produced thereby
AU2010211376B2 (en)	2009-02-06	2013-08-22	Egalet Ltd.	Pharmaceutical compositions resistant to abuse
PL2398808T3 (pl)	2009-02-17	2014-04-30	Mallinckrodt Llc	Sposób redukcyjnego alkilowania normorfinanów
US8436174B2 (en)	2009-02-23	2013-05-07	Mallinckrodt Llc	(+)-morphinanium quaternary salts and processes for their production
JP2012518651A (ja)	2009-02-23	2012-08-16	マリンクロッドインコーポレイテッド	（＋）−モルフィナニウムｎ−オキシドおよびそれらの生成方法
US20100227876A1 (en)	2009-03-06	2010-09-09	Rechfensen Llp	Methods of Reducing Side Effects of Analgesics
ES2706407T3 (es)	2009-03-10	2019-03-28	Euro Celtique Sa	Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
CN102365083A (zh)	2009-03-18	2012-02-29	赢创罗姆有限公司	采用包含聚合物混合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
JP5619130B2 (ja)	2009-03-18	2014-11-05	エボニックレームゲゼルシャフトミットベシュレンクテルハフツングＥｖｏｎｉｋＲｏｅｈｍＧｍｂＨ	中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
EP2413937A1 (en)	2009-04-02	2012-02-08	Shire LLC	Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
US20120065179A1 (en)	2009-04-14	2012-03-15	YKI, Ytemiska Institutet AB	Prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
WO2010123999A2 (en)	2009-04-21	2010-10-28	Auspex Pharmaceuticals, Inc.	1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
AU2010238945B2 (en)	2009-04-24	2013-10-24	Omya International Ag	Particulate material for controlled release of active ingredients
WO2010141505A1 (en)	2009-06-01	2010-12-09	Protect Pharmaceutical Corporation	Abuse-resistant delivery systems
GB0909680D0 (en)	2009-06-05	2009-07-22	Euro Celtique Sa	Dosage form
CN102803267A (zh)	2009-06-11	2012-11-28	马林克罗特有限公司	通过催化氢转移的6-α-氨基N-取代的吗啡喃的制备
FR2946533A1 (fr)	2009-06-12	2010-12-17	Ethypharm Sa	Reduction des fluctuations plasmatiques d'opioides.
US8829020B2 (en)	2009-07-16	2014-09-09	Mallinckrodt Llc	Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PL2997965T3 (pl)	2009-07-22	2019-06-28	Grünenthal GmbH	Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
ES2534908T3 (es)	2009-07-22	2015-04-30	Grünenthal GmbH	Forma de dosificación de liberación controlada extruida por fusión en caliente
GB0914338D0 (en)	2009-08-17	2009-09-30	Johnson Matthey Plc	Improved process
MX348262B (es)	2009-09-08	2017-06-05	Signature Therapeutics Inc *	Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.
WO2011041470A2 (en)	2009-09-30	2011-04-07	Mallinckrodt Inc.	Sustained-release opiate and opiate derivative compositions
US8901113B2 (en)	2009-09-30	2014-12-02	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse
MX347105B (es)	2010-05-10	2017-04-12	Euro Celtique Sa	Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX340188B (es)	2010-05-10	2016-06-30	Euro-Celtique S A *	Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
JP5840201B2 (ja)	2010-05-10	2016-01-06	ユーロ−セルティークエス．エイ．	活性剤を負荷した顆粒と追加の活性剤の組合せ
GB201020895D0 (en)	2010-12-09	2011-01-26	Euro Celtique Sa	Dosage form

2011
- 2011-05-10 MX MX2012013119A patent/MX347105B/es active IP Right Grant
- 2011-05-10 EA EA201291211A patent/EA201291211A1/ru unknown
- 2011-05-10 DE DE112011101605T patent/DE112011101605T5/de not_active Withdrawn
- 2011-05-10 CA CA2739751A patent/CA2739751C/en not_active Expired - Fee Related
- 2011-05-10 PE PE2012002146A patent/PE20130657A1/es not_active Application Discontinuation
- 2011-05-10 AU AU2011252039A patent/AU2011252039B2/en not_active Ceased
- 2011-05-10 MY MYPI2012004553A patent/MY157673A/en unknown
- 2011-05-10 CH CH02357/12A patent/CH705273B1/de not_active IP Right Cessation
- 2011-05-10 SE SE1251371A patent/SE1251371A1/sv not_active Application Discontinuation
- 2011-05-10 GB GB1219275.3A patent/GB2492037A/en not_active Withdrawn
- 2011-05-10 NZ NZ603497A patent/NZ603497A/en not_active IP Right Cessation
- 2011-05-10 KR KR1020127029438A patent/KR20130030260A/ko not_active Ceased
- 2011-05-10 PH PH1/2012/502011A patent/PH12012502011A1/en unknown
- 2011-05-10 SG SG2012075040A patent/SG184523A1/en unknown
- 2011-05-10 EP EP11718747.6A patent/EP2568967B2/en active Active
- 2011-05-10 ES ES201290081A patent/ES2408343B2/es not_active Expired - Fee Related
- 2011-05-10 BR BR112012028773A patent/BR112012028773A2/pt not_active Application Discontinuation
- 2011-05-10 TW TW103137424A patent/TWI590835B/zh not_active IP Right Cessation
- 2011-05-10 US US13/697,197 patent/US9700508B2/en not_active Expired - Fee Related
- 2011-05-10 AR ARP110101621A patent/AR083150A1/es unknown
- 2011-05-10 JP JP2013509554A patent/JP5671609B2/ja not_active Expired - Fee Related
- 2011-05-10 AP AP2012006606A patent/AP3441A/xx active
- 2011-05-10 WO PCT/EP2011/057566 patent/WO2011141488A2/en not_active Ceased
- 2011-05-10 TW TW100116427A patent/TWI483748B/zh not_active IP Right Cessation
- 2011-05-10 KR KR1020157004528A patent/KR101858797B1/ko not_active Expired - Fee Related
- 2011-05-10 CN CN201610284534.0A patent/CN105832687A/zh active Pending
- 2011-05-10 CN CN2011800231922A patent/CN102946870A/zh active Pending
- 2011-05-10 NZ NZ700732A patent/NZ700732A/en not_active IP Right Cessation
- 2011-10-05 UA UAA201212796A patent/UA106278C2/uk unknown
2012
- 2012-10-08 EC ECSP12012236 patent/ECSP12012236A/es unknown
- 2012-10-09 TN TNP2012000488A patent/TN2012000488A1/en unknown
- 2012-10-10 ZA ZA2012/07603A patent/ZA201207603B/en unknown
- 2012-10-22 NI NI201200157A patent/NI201200157A/es unknown
- 2012-10-26 CL CL2012003012A patent/CL2012003012A1/es unknown
- 2012-10-29 CR CR20120549A patent/CR20120549A/es unknown
- 2012-10-30 IL IL222772A patent/IL222772B/en not_active IP Right Cessation
- 2012-11-05 DK DKPA201270677A patent/DK178741B1/da not_active IP Right Cessation
- 2012-11-08 CO CO12201488A patent/CO6640216A2/es unknown
- 2012-11-09 GT GT201200304A patent/GT201200304A/es unknown
- 2012-11-26 NO NO20121414A patent/NO20121414A1/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
GT201200304A (es)	2014-06-09
AP2012006606A0 (en)	2012-12-31
DK201270677A (en)	2012-11-05
SE1251371A1 (sv)	2012-12-27
CO6640216A2 (es)	2013-03-22
JP2013526508A (ja)	2013-06-24
AU2011252039A1 (en)	2012-11-08
NI201200157A (es)	2013-02-05
MX347105B (es)	2017-04-12
SG184523A1 (en)	2012-11-29
EP2568967B1 (en)	2018-10-24
TN2012000488A1 (en)	2014-04-01
EA201291211A1 (ru)	2013-05-30
NO20121414A1 (no)	2013-02-11
ES2408343R1 (es)	2013-08-28
CN105832687A (zh)	2016-08-10
GB2492037A (en)	2012-12-19
US9700508B2 (en)	2017-07-11
BR112012028773A2 (pt)	2016-07-19
CR20120549A (es)	2013-03-08
NZ603497A (en)	2015-02-27
ZA201207603B (en)	2014-12-23
PE20130657A1 (es)	2013-06-15
ES2408343A2 (es)	2013-06-20
GB201219275D0 (en)	2012-12-12
DE112011101605T5 (de)	2013-04-25
CH705273B1 (de)	2016-06-15
CN102946870A (zh)	2013-02-27
KR20130030260A (ko)	2013-03-26
MY157673A (en)	2016-07-15
IL222772A0 (en)	2012-12-31
DK178741B1 (da)	2016-12-19
PH12012502011A1 (en)	2016-05-25
JP5671609B2 (ja)	2015-02-18
MX2012013119A (es)	2013-02-11
NZ700732A (en)	2015-08-28
UA106278C2 (uk)	2014-08-11
KR101858797B1 (ko)	2018-05-16
KR20150028367A (ko)	2015-03-13
TW201206501A (en)	2012-02-16
ECSP12012236A (es)	2013-02-28
AR083150A1 (es)	2013-02-06
AP3441A (en)	2015-10-31
EP2568967B2 (en)	2022-07-27
TWI590835B (zh)	2017-07-11
TW201503913A (zh)	2015-02-01
CA2739751A1 (en)	2011-11-10
EP2568967A2 (en)	2013-03-20
CA2739751C (en)	2014-08-12
US20130178492A1 (en)	2013-07-11
WO2011141488A2 (en)	2011-11-17
WO2011141488A3 (en)	2012-04-05
AU2011252039B2 (en)	2014-06-12
IL222772B (en)	2018-11-29
ES2408343B2 (es)	2014-07-17
TWI483748B (zh)	2015-05-11

Publication	Publication Date	Title
CL2012003012A1 (es)	2014-02-21	Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
IL274602A (en)	2020-06-30	Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
JP2007527914A5 (es)	2008-04-10
IL241361A (en)	2017-01-31	Use of a medicinal product containing a main species of her2-acidic variants for the preparation of a pharmaceutical product
SI2120878T1 (sl)	2014-12-31	Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
IL206789A (en)	2015-11-30	A converted cyclic amide compound, a pharmaceutical preparation containing the compound and the use of a compound or pharmaceutical preparation in a pharmaceutical preparation
IL223783B (en)	2018-06-28	Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
CL2011002248A1 (es)	2012-01-27	Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
ATE517619T1 (de)	2011-08-15	Stabilisierte pharmazeutische zusammensetzung mit fesoterodin
PT2344198T (pt)	2020-12-04	Preparações farmacêuticas à base de lípidos para aplicação tópica
BRPI0818193A2 (pt)	2017-12-12	composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
CL2011001621A1 (es)	2012-03-30	Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
CL2007002921A1 (es)	2008-05-30	Forma solida de dosificacion farmaceutica de administracion oral, que comprende una forma cristalina o amorfa de un compuesto microincluido en un polimero ionico insoluble en agua en proporcion 5:1 a 1:5; y metodo de preparacion.
CL2013000444A1 (es)	2013-08-23	Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion.
BRPI0913822A2 (pt)	2015-10-20	forma farmacêutica oral e uso da forma farmacêutica
EP2351581A4 (en)	2013-02-27	VACCINE COMPOSITION AGAINST MALE AND CLAUSE DISEASE AND PREPARATION METHOD THEREFOR
IL204658A (en)	2015-10-29	Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt
BRPI1012066A2 (pt)	2018-06-19	composição para o cuidado oral , e, métodos para preparar a composição para o cuidado oral e para administrar um composto de zinco a um indivíduo animal ou humano em necessidade do mesmo
CL2014000844A1 (es)	2014-09-12	Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
FR2934156B1 (fr)	2010-09-24	Medicament appetissant a administration orale sous forme solide
EP2474522A4 (en)	2013-03-20	AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
BRPI1013988A2 (pt)	2016-04-05	composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CL2008000610A1 (es)	2008-09-05	Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CO6801754A2 (es)	2013-11-29	Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida